type: position_score
table:
  filename: ENCFF411RMT.tabix.bed.gz
  header_mode: none
  zero_based: true
  format: tabix
  chrom:
    column_index: 0
  pos_begin:
    column_index: 1
  pos_end:
    column_index: 2
scores:
- id: TF_ChIP-seq_ENCSR177XCS
  column_index: 3
  type: float
  desc: signal
  histogram:
    type: number
    number_of_bins: 100
meta:
  summary: 'ChIP-seq ENCSR177XCS [TISSUE: Homo sapiens K562, TARGET: BRD9]'
  description: "**status**: released\n\n**biological\\_replicates**: Rep 1, Rep 2\n\
    \n**summary**: \n\n**output\\_type**: optimal IDR thresholded peaks\n\n**audit\\\
    _internal\\_action**: Archived analysis {ENCAN991YSP|/analyses/ENCAN991YSP/} has\
    \ in progress subobject quality standard {encode3-tf-chip|/quality-standards/encode3-tf-chip/}\n\
    \n**audit\\_internal\\_action**: File {ENCFF411RMT|/files/ENCFF411RMT/} with status\
    \ 'released' is derived from file {ENCFF419RSJ|/files/ENCFF419RSJ/} with status\
    \ 'archived'.\n\n**audit\\_warning**: Processed alignments file {ENCFF410BXB|/files/ENCFF410BXB/}\
    \ processed by ChIP-seq ENCODE3 GRCh38 pipeline has 16789551 usable fragments.\
    \ The minimum ENCODE standard for each replicate in a ChIP-seq experiment targeting\
    \ BRD9-human and investigated as a transcription factor is 10 million usable fragments.\
    \ The recommended value is > 20 million, but > 10 million is acceptable. (See\
    \ {ENCODE ChIP-seq data standards|/data-standards/chip-seq/} )"
  labels:
    reference_genome: hg38/genomes/GRCh38-hg38
    accession: ENCSR177XCS
    status: released
    assay_term_name: ChIP-seq
    simple_biosample_summary: ''
    biosample_summary: Homo sapiens K562
    replication_type: isogenic
    biosample_ontology: /biosample-types/cell_line_EFO_0002067/
    perturbed: false
    doi: 10.17989/ENCSR177XCS
    date_created: '2015-09-24T23:22:57.323193+00:00'
    date_released: '2018-01-26'
    submitter_comment: We note that this ChIP-seq experiment was performed using an
      antibody for which we have provided a compliant primary characterization but
      no secondary characterization.  A secondary characterization using IP-MS was
      attempted, but the experiment failed.  There is no remaining antibody from this
      lot number and therefore additional secondary characterizations cannot be attempted.
      However, because the replicate ChIP-seq datasets passed the ENCODE IDR ChIP-seq
      data quality standards, we are releasing the data to the public.
    target: BRD9